How do new insights from the XARENO study impact

treatment options for patients with AF and advanced CKD?

In this episode, Dr Manesh Patel and Dr Peter Rossing expand upon the XARENO 2-year outcomes data presented at the ACC 2023 congress. The experts provide cardiology and endocrinology perspectives into how these results add to the wealth of randomized clinical trial and real-world data to determine the treatment options for patients with AF and advanced CKD.

The views and opinions expressed throughout this podcast are those of the speakers based on their expertise and do not necessarily reflect those of Bayer. The Bayer product rivaroxaban is discussed during this episode.

Rivaroxaban is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack.

Further details:

• The ACC 2023 presentation of the 2-year XARENO data can be accessed here:

https://www.abstractsonline.com/pp8/#!/10674/presentation/19112

• The 1-year results from the XARENO study can be found here

https://www.ahajournals.org/doi/10.1161/circ.142.suppl_3.13927, here

https://www.researchgate.net/profile/Kai-Hahn2/publication/360217368_ACC22_XARENO_Poster_Final/links/6268ee8e8e6d637bd101

b8d0/ACC22-XARENO-Poster-Final.pdf and here

https://www.jacc.org/doi/abs/10.1016/S0735-1097%2822%2901192-5

• The XARENO study design is available here:

https://journals.viamedica.pl/kardiologia_polska/article/view/86346

• Access the ROCKET AF manuscript here:

https://www.nejm.org/doi/full/10.1056/nejmoa1009638

• The 2020 ESC guidelines for AF treatment can be accessed here:

https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Atrial-FibrillationManagement

• AF treatment guidelines published by the AHA/ACC/AHS in 2019 can be found here:

230313-XARENO 2 year outcomes podcast shownotes-draft3 4

https://www.ahajournals.org/doi/10.1161/CIR.0000000000000665

• For anticoagulant dosing information, see the European labels for apixaban

(http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-

_Product_Information/human/002148/WC500107728.pdf), dabigatran

(http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-

_Product_Information/human/000829/WC500041059.pdf), edoxaban

(http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-

_Product_Information/human/002629/WC500189045.pdf), rivaroxaban

(https://www.ema.europa.eu/documents/product-information/xarelto-epar-productinformation_en.pdf) and warfarin (https://www.medicines.org.uk/emc/product/3064/smpc)

MA-M_RIV-ALL-1368-2 & MA-M_RIV-ALL-1370-2